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Abstract
NOTCH proteins constitute a receptor family with a widely conserved role in cell cycle, growing and development regulation. 
NOTCH1, the best characterised member of this family, regulates the expression of key genes in cell growth and angiogenesis, 
playing an essential role in cancer development. These observations provide a relevant rationale to propose the inhibition 
of the intracellular domain of NOTCH1 (Notch1-IC) as a strategy for treating various types of cancer. Notch1-IC stability 
is mainly controlled by post-translational modifications. FBXW7 ubiquitin E3 ligase-mediated degradation is considered 
one of the most relevant, being the previous phosphorylation at Thr-2512 residue required. In the present study, we describe 
for the first time a new regulation mechanism of the NOTCH1 signalling pathway mediated by DYRK2. We demonstrate 
that DYRK2 phosphorylates Notch1-IC in response to chemotherapeutic agents and facilitates its proteasomal degradation 
by FBXW7 ubiquitin ligase through a Thr-2512 phosphorylation-dependent mechanism. We show that DYRK2 regulation 
by chemotherapeutic agents has a relevant effect on the viability, motility and invasion capacity of cancer cells expressing 
NOTCH1. In summary, we reveal a novel mechanism of regulation for NOTCH1 which might help us to better understand 
its role in cancer biology.
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Introduction
NOTCH proteins (NOTCH1-4) constitute a receptor family 
with a widely conserved role in cell cycle, growing, develop-
ment regulation and cell fate determination [1]. Most of the 
canonical Notch ligands are transmembrane proteins with an 
extracellular domain primarily comprised of multiple EGF 
(Epidermal Growth Factor) repeated similar structures [2]. 
The best characterised member of this family is NOTCH1, 
which regulates the expression of key genes in cell growth 
and angiogenesis, playing an essential role in cancer devel-
opment. After ligand coupling, NOTCH1 is activated and 
the receptor is cleaved by a gamma-secretase, leading to 
the formation of a peptide sequence that corresponds to 
the intracellular domain of NOTCH1 (Notch1-IC) [3, 4]. 
In human cells, once Notch1-IC enters the nucleus, and 
together with the DNA-binding protein CSL (CBF1—Sup-
pressor of Hairless—LAG1) and the co-activator MAML1 
(Mastermind-like transcriptional co-activator 1), it stimu-
lates the transcription of target genes related to processes 
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such as proliferation, angiogenesis, cell survival and migra-
tion [5, 6].
Functional studies implicate Notch signalling in essen-
tially all of the hallmarks of cancer, being associated with 
abnormal expression, high mutation rate and poor survival in 
several cancers such as lung, breast, gastric or lymphoid can-
cer [7–11]. This oncogenic function of NOTCH in human 
cancers is related with its capacity to increase cell growth, 
centered on the ability to induce the expression of Myc [12, 
13] and to enhance PI3K-Akt signalling [14]. Additionally, 
NOTCH has also been described as a mediator of chemore-
sistance in various human cancers [15, 16]. These observa-
tions have provided a rationale for pharmacologic inhibi-
tion of Notch1-IC as a potential strategy for treating various 
cancers [17].
Another potential way to regulate the NOTCH pathway 
is modulating the activity or stability of Notch1-IC, which 
is controlled by protein–protein interactions, endocytosis or 
post-translational modifications (ubiquitination and phos-
phorylation) [18, 19]. From among them, NOTCH1 degra-
dation by the ubiquitin E3 ligase FBXW7 is considered to 
be one of the most relevant [20]. FBXW7 binds directly to 
Notch1-IC promoting its polyubiquitination and proteasomal 
degradation, which requires phosphorylation at Thr-2512 
residue [21–23]. To date, only homeodomain-interacting 
protein kinase 2 (HIPK2) and MEKK1 have been described 
to phosphorylate NOTCH1 at Thr-2512, promoting its sub-
sequent proteasomal degradation [24, 25].
Dual-specificity tyrosine-phosphorylation-regulated 
kinase 2 (DYRK2) is a Ser/Thr kinase that plays key roles 
in the regulation of proliferation, cell differentiation and sur-
vival [26]. DYRK2 contributes to the regulation of various 
signalling pathways via the phosphorylation of relevant pro-
teins such as NFAT, p53, c-Jun, c-Myc, eIF2Bε, tau, hPXR, 
glycogen synthase, CRMP4, 4E-BP1, Snail, katanin and 
SIAH2 [26–30]. Several studies highlighted the importance 
of DYRK2 impairing the development and progression of 
human cancers, such as non-small cell lung cancer, esoph-
ageal adenocarcinomas, breast cancer and ovarian serous 
adenocarcinoma [31–34]. In agreement, DYRK2 knockdown 
increases cancer cell growth and invasion [29]. Similarly, 
DYRK2 reduces epithelial–mesenchymal transition (EMT) 
by degrading SNAIL in ovarian cancer [33]. In response to 
genotoxic stress, ataxia-telangiectasia mutated (ATM) phos-
phorylates and stabilises DYRK2, which in turn phosphoryl-
ates p53 at Ser46 promoting apoptosis [35, 36].
This study describes for the first time DYRK2 as a new 
upstream negative regulator of the NOTCH1 signalling 
pathway. We prove that DYRK2 directly interacts with and 
phosphorylates Notch1-IC at Thr-2512 facilitating its pro-
teasomal degradation by FBXW7. Moreover, we found that 
DYRK2 modulation by chemotherapeutic agents has a rel-
evant effect on the viability, motility and invasion capacity 
of cancer cells expressing NOTCH1. In summary, we reveal 
DYRK2 as a novel negative regulator of NOTCH1 levels 
and activity, which represents a new control mechanism of 
the expression and function of this transcription factor with 
potential implications in cancer.
Materials and methods
Cell culture, transfection and reagents
HEK-293T (wt/DYRK2−/−/HIPK2−/−), HeLa (wt/
DYRK2−/−/DYRK1A−/−), MDA-MB-468 (wt/DYRK2−/−), 
MDA-MB-231 (wt/DYRK2−/−), MOR, MCF7, CHO 
and A549 cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% FBS 
(Fetal Bovine Serum) and 1% (v/v) penicillin/streptomycin 
(Sigma-Aldrich, St Louis, MO, USA) at 37 °C in a humidi-
fied atmosphere containing 5%  CO2. H727 cells were main-
tained in Roswell Park Memorial Institute (RPMI) medium 
at the same conditions. Cell lines were obtained from ATCC 
(LGC Standards, Teddington, Middlesex, UK) and were rou-
tinely tested to be free of mycoplasma and cross contamina-
tion. Cell lines validation was performed by a multiplex PCR 
with Geneprint10 System (Promega, Madison, WI, USA). 
MG-132 was from Enzo Life Science (Lausen, Switzerland). 
Transient transfections were carried out with Roti-Fect (Carl 
Roth, Karlsruhe, Germany) and harvested between 36 and 
48 h after transfection. DNA amounts in each transfection 
were kept constant after the addition of empty expression 
vector. DYRK2 and Notch1-IC plasmids were previously 
described or generated in this lab by standard cloning tech-
niques [30]. Point mutants were produced by conventional 
point mutagenesis. HeLa control and  DYRK1A−/− cells 
were a gift from Dr. Susana de la Luna (Centre for Genomic 
Regulation, Barcelona, Spain). DYRK2-analogue-sensitive 
expression plasmid (GFP-DYRK2-AS) was previously 
described [37]. Myc-tagged Notch1-IC and 4xCSL vectors 
were provided by Dr. Hee-Sae Park (Korea Basic Science 
Institute, Gwang Ju, South Korea). pLentiCRISPr-V2 was 
a gift from Dr. Feng Zhang (Addgene plasmid # 52961). 
Flag-tagged Notch2-IC and Notch4-IC vectors were a gift 
from Dr. Raphael Kopan (Addgene plasmids # 20184 and 
# 20186). HA-tagged Notch1-IC plasmid was a gift from 
Dr. Urban Lendahl (Addgene plasmid # 47618). HA-tagged 
Notch1-IC WT and mutant plasmids were kindly provided 
by Dr. Aifantis (NYU Langone Medical Center, New 
York, USA). Flag-FBXW7-ΔFbox was kindly provided 
by Dr. Rocio Sancho (Centre for Stem Cells & Regenera-
tive Medicine King’s College London, UK). Adriamycin 
(ADR), harmine, etoposide (ETP) and the rest of the rea-
gents were from Sigma-Aldrich. PP1 analogue II 1NM-PP1 
(SC-203214) was obtained from Santa Cruz Biotechnology 
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(Santa Cruz, California, USA). Scramble control oligonu-
cleotide siRNA non-targeting pool (D-001810) and ON-
TARGET plus SMARTpool against DYRK2 (L-004730-00) 
were purchased from Dharmacon (Waltham, MA, USA). 
DYRK2 human recombinant protein was purchased from 
Abcam (Cambridge, UK).
Generation of CRISPR/Cas9‑cell lines
The endogenous DYRK2 gene was knocked out by trans-
fecting cells with pLentiCRISPR-v2 (which codes for Cas9 
and a puromycin cassette) containing gRNAs against the 
first exon of the short DYRK2 isoform or a combination 
of gRNAs against the first and the last exon. For HeLa and 
MDA-MB-468 DYRK2-KO cells, the gRNA sequence 
used was GCT TGC CAG TGG TGC CAG AG and for MDA-
MB-231 and HEK-293T DYRK2-KO cells, the gRNAs used 
were N-term sequence GCT TGC CAG TGG TGC CAG AG 
and C-term sequence GAA GCT GAG CTA GAA GGT GG. 
Control cells were transfected with the empty pLentiCRIS-
PRV2 vector. After transfection, cells were exposed to 2 μg/
ml of puromycin for 2 days followed by a medium exchange. 
Surviving cells were clonally selected (in the case of con-
trol cells were used as pool population) by serial dilution, 
and positive clones were identified by genomic analysis and 
western blot.
Western blotting and antibodies
Soluble fractions were obtained after lysis of cells in NP-40 
buffer [20 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM 
phenylmethylsulfonyl fluoride, 10 mM NaF, 0.5 mM sodium 
orthovanadate, leupeptine (10 μg/ml), aprotinin (10 μg/
ml), 1% (v/v) NP-40, and 10% (v/v) glycerol]. Proteins 
were diluted and boiled at 95 °C in SDS buffer, resolved on 
sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE), 
transferred to PVDF membranes, blocked with non-fat milk 
in TTBS buffer and incubated with primary antibodies. The 
washed membranes were incubated with appropriate sec-
ondary antibodies coupled to horseradish peroxidase, which 
were detected by chemiluminescence using Clarity™ West-
ern ECL Substrate (Bio-rad Hercules, California, USA). 
Antibodies against the FLAG epitope (clone M2, A2220) 
and anti-β-actin (A5316) were purchased from Sigma 
Aldrich; anti-ubiquitin (P4D1, 3936S) from Cell Signaling 
Technology (Danvers, Massachusetts, USA). Anti-Notch1 
(ab25374), anti-Hes1 (ab71559) and anti-Hes5 (ab25374) 
were obtained from Abcam. Anti-HA (clone 3F10), anti-myc 
(clone 9E10), anti-GFP (11814460001) (Roche Molecular 
Biochemical) and anti-phosphoserine (AB1603) (Millipore, 
Burlington, Massachusetts, USA) were from the indicated 
suppliers. Anti-DYRK2 (H80; sc-66867) and anti-DYRK1A 
(RR7; sc-100376) antibodies were obtained from Santa Cruz 
Biotechnology. Secondary horseradish peroxidase-coupled 
antibodies were purchased from Jackson ImmunoResearch 
Laboratories (Cambridgeshire, UK). Texas Red goat anti-
rabbit IgG antibody (T-6391) was from Thermo Fisher Sci-
entific (Waltham, Massachusetts, USA).
Immunoprecipitation
Cells were washed in PBS and lysed in IP buffer [50 mM 
Hepes (pH 7.5), 50 mM NaCl, 1% (v/v) Triton X-100, 2 mM 
EDTA, 10 mM sodium fluoride, 0.5 mM sodium orthova-
nadate, 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 1 mM 
PMSF]. Cell lysates were pre-cleared with protein A/G 
Sepharose (Santa Cruz) and immunoprecipitation was per-
formed on a rotating wheel upon the addition of 1 μg of the 
indicated antibodies and 25 μl of protein A/G Sepharose 
beads. Immunoprecipitated proteins were then washed for 
five times in IP buffer and eluted in 2 × SDS sample buffer, 
followed by western blotting.
Luciferase reporter assays
Cells were collected in PBS and lysed in luciferase assay 
buffer (25 mM Tris–phosphate pH 7.8, 8 mM MgCl2, 1 mM 
DTT, 1% Triton X-100 and 7% glycerol) during 15 min at 
room temperature in a horizontal shaker. Luciferase assay 
was performed using Luciferase Assay Reagent (Promega) 
according to the manufacturer’s instructions. Luciferase 
activity was measured using an Autolumat LB 953 (Berthold 
Technologies GmbH, Bad Wildbad, Germany) and normal-
ised with protein concentration.
Immunofluorescence
Cells were seeded on glass coverslips and 48 h after trans-
fection fixed with 3.7% of pre-warmed paraformaldehyde/
PBS for 10 min, permeabilized with 0.1% Triton X-100/
PBS for 15 min, blocked with 3% BSA/PBS and incubated 
overnight with primary antibodies. After being washed with 
PBS and incubated for 45 min with the secondary antibody, 
cells were mounted on glass slides with mounting medium-
containing DAPI (Vectashield Burlingame, CA, USA). Fluo-
rescence images were captured using an LSM 5 EXCITER 
(Carl Zeiss MicroImaging GmbH, Oberkochen, Germany) 
confocal laser scanning microscope using a 40 ×/1.30 oil 
objective (EC Plan-Neofluar) and ZEN 2008 software (Carl 
Zeiss MicroImaging GmbH). To determine fluorescent sig-
nal, colocalization between different channels the Coloc_2 
module was used. The degree of channel colocalization was 
analysed by considering the following indexes: thresholded 
Manders’ coefficients A and B and Pearson’s coefficient. 
To evaluate the spatial relations between channel intensity, 
we used the ImageJ tool RGB Profiler to create a profile 
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of fluorescence intensity values across a line drawn on the 
image.
mRNA extraction and qPCR
Total RNA was extracted using the High Pure RNA Isolation 
kit (Roche Diagnostics, Switzerland), reverse transcription 
performed with the iScript cDNA Synthesis kit (Bio-Rad) 
and real-time PCR carried out in an iCYCLER detection 
system (Bio-Rad) with iQTM SYBR Green Supermix (Bio-
Rad). Amplification efficiencies were validated and normal-
ised against HPRT, and fold change in gene expression was 
calculated using the 2−ΔΔCt method. Primer sequences are 
available upon request.
In vitro phosphorylation
Immunoprecipitated myc-tagged Notch1-IC endogenous 
protein was incubated with 50 ng of commercial recombi-
nant DYRK2 protein (Millipore, 14-669) in kinase buffer 
(20 mM Hepes pH 7.5, 10 mM  MgCl2, 1 mM DTT) with or 
without ATP (0.1 μM). After 60 min of incubation at 37 °C, 
reactions were stopped using 1 M glycine pH 2.5 in agitation 
for 20 min at room temperature and A/G beads (Santa Cruz 
Biotecnology) were removed by centrifugation. Finally, 
readjustment of pH levels of the supernatant was performed 
employing 1 M Tris–HCl pH 7.5.
Cell viability and flow cytometry analyses
For apoptosis studies, cells were harvested and washed in 
cold PBS and then resuspended in binding buffer consist-
ing of 10 mM Hepes, 140 mM NaCl and 2.5 mM  CaCl2 pH 
7.4. Cells were stained with Annexin V, Alexa Fluor 488 
conjugate (Molecular Probes by Life Technologies, Carls-
bad, CA, USA) and propidium iodide. Cell cycle distribution 
and apoptosis were determined by BD FACSCanto™ flow 
cytometer (BD Biosciences, San Jose, CA, USA) using BD 
FACSDiva™ software. For cytotoxicity assay, cells were 
seeded in a 96-well plate and after 12 h YOYO-1 (Life 
Technologies) was added to a final concentration of 0.1 μM. 
Object counting analysis was performed using the cell imag-
ing system IncuCyte HD (Essen BioScience).
Cell motility assay
Cells were seeded in a 96-well Essen ImageLock plate 
(Essen BioScience, Ann Arbor, Michigan, USA) 24  h 
after transfection and grown to confluence. After 12 h, the 
scratches were made using the 96-pin WoundMaker (Essen 
BioScience), followed by incubation with 10 ng/ml of mito-
mycin C. Wound images were taken every 60 min for 24 h 
and the data analysed by the integrated metric Relative 
Wound Density part of the live content cell imaging system 
IncuCyte HD (Essen BioScience).
Cell invasion assay
Invasion assays were performed in Boyden chamber using 
a 48-well Neuro Probe, Inc. insert system (Gaithersburg, 
MD, USA). Polyethylene membrane inserts (8.0 μm pore 
size) were precoated with 200 μg/μl of  Matrigel® Matrix 
 (Corning®, Corning, NY, USA) (in coating buffer 0.01 M 
Tris and 0.7% NaCl). Cells were subcultured in an mw6 
plate, and 24 h prior the assay, FBS was removed from the 
media and ADR was added in the specific conditions. Then, 
cells were seeded with 2.5 × 104 cells per insert (cells sus-
pended in 50 μl in DMEM, in addition to 25 μl FBS free 
DMEM in the bottom side of the chamber) and incubated at 
37 °C, 5%  CO2 for 12 h. Then, the membrane was washed at 
least three times for 10 min with PBS. The membranes were 
then cut out of the inserts by a scalpel, dyed in methyl violet 
for 30 min and mounted between two thin cover slips. The 
total number of migrated cells was counted for each group 
(n = 4) with an inverted microscope. Only cells which had 
completely migrated through the membrane were counted.
Enrichment of His‑tagged proteins
Cells were collected in PBS and pellets resuspended in lysis 
buffer (6 M guanidinium-HCl, 0.1 M  Na2HPO4/NaH2PO4, 
0.01 M Tris–HCl [pH 8], 5 mM imidazole and 0.01 M 
β-mercaptoethanol). Samples were sonicated and cell debris 
was removed by centrifugation. Supernatants were mixed 
with 75 μl of equilibrated Ni–NTA resin (Quiagen, Hilden, 
Germany), followed by incubation for 4 h at room temper-
ature on a rotating wheel. Precipitates were washed once 
with lysis buffers, once in wash buffer (8 M urea, 0.1 M 
 Na2HPO4/NaH2PO4, 0.01 M Tris–HCl [pH 6.8], 5 mM imi-
dazole, and 0.01 M β-mercaptoethanol), and twice in wash 
buffer plus 0.1% Triton X-100. Proteins were eluted in 75 μl 
of 0.2 M imidazole, 0.15 M Tris–HCl (pH 6.8), 30% glyc-
erol, 0.72 M β-mercaptoethanol and 5% SDS for 20 min at 
room temperature with gentle agitation and further analysed 
by immunoblotting.
Data analysis
Protein abundance in tumor tissue was obtained from The 
Human Protein Atlas database as antibody staining level (not 
detected, low, medium and high) per patient [38]. Data were 
accessed via the R hpar package. Gene alteration frequen-
cies were calculated using the TCGA PanCancer dataset that 
includes 10967 samples across 33 different tumor types [39]. 
To calculate the alteration frequencies, the number of sam-
ples containing a missense/non-sense mutation or a deep 
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Fig. 1  NOTCH1 protein levels are modulated by DYRK2. a HEK-
293T cells were transfected (2 × 105 cells in a 35-mm dish, increas-
ing amounts of DYRK2) with the indicated plasmids and lysed 48 h 
after transfection. Protein expression was evaluated by immunoblot-
ting. We show a representative blot of three independent experiments. 
b HEK-293T cells (2 × 105 cells in a 35 mm dish) were transfected 
with the indicated amounts of DYRK2, harvested and lysed. One 
fraction was used to analyse endogenous Notch1-IC protein levels, 
while another aliquot was used to analyse Notch1-IC mRNA levels 
by quantitative PCR. Data are mean ± SD of n = 3. We show a rep-
resentative blot of three independent experiments. c HEK-293T cells 
were transfected with DYRK2 or scrambled (control) siRNAs, lysed 
after 4 days of culture and Notch1-IC or DYRK2 analysed by western 
blot. We show a representative blot of three independent experiments. 
d Notch1-IC and DYRK2 endogenous protein levels were analysed 
in the indicated cell lines by immunoblotting. We show a representa-
tive blot of three independent experiments (left panel). Notch1-IC and 
DYRK2 signals from three independent experiments were quantified, 
normalised to actin protein levels and correlation was analysed (right 
panel). e Endogenous protein levels of DYRK2 and Notch1-IC were 
evaluated in MDA-MB-231, MDA-MB-468, HeLa and HEK-293T 
both WT and  DYRK2−/− by immunoblot. We show a representative 
blot of three independent experiments
 R. Morrugares et al.
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deletion for a given gene was divided by the total number 
of samples in a given cancer type. Data were accessed via 
the cBioPortal web service using the R cgdsr package [40]. 
Images were evaluated and quantified using the Image J 
(http://rsbwe b.nih.gov/ij/). Data are expressed as mean ± SD. 
Differences were analysed by Student’s t test. P < 0.05 was 
considered significant. Statistical analysis was performed 
using GraphPad  Prism® version 6.01 (GraphPad, San Diego, 
CA, USA).
Results
Notch1‑IC protein levels are modulated by DYRK2
To identify new potential DYRK2 interaction partners, we 
performed an immunoprecipitation assay followed by mass 
spectrometry (Fig. S1a and Supplementary Materials and 
methods). As NOTCH1 and other members of the family 
showed positive results, we decided to focus on this protein 
in detail. We first co-expressed Notch1-IC alone or with 
increasing amounts of DYRK2 in HEK-293T cells. Expres-
sion of DYRK2 resulted in a dose-dependent decrease in 
Notch1-IC protein levels, which was accompanied by the 
appearance of slower migrating bands (Fig. 1a). The activ-
ity of the rest of the members of human DYRK subfamily 
protein kinases (DYRK1A, DYRK1B, DYRK2, DYRK3, 
and DYRK4) was also analysed. As shown in Supplemen-
tary Figure S1b, DYRK1A and DYRK1B overexpression 
showed a similar effect as compared to DYRK2, which was 
not observed with DYRK3 and 4. Similarly, DYRK2 overex-
pression resulted in a decrease of the rest of NOTCH human 
family members (NOTCH2, NOTCH3 and NOTCH4) (Fig. 
S1c).
Next, we decided to analyse the impact of DYRK2 expres-
sion on the levels of endogenous Notch1-IC. Transfection 
of increasing amounts of DYRK2 led to a dose-dependent 
decrease of endogenous Notch1-IC protein levels without 
affecting its mRNA expression (Fig. 1b). Similar results 
were obtained with DYRK1B (Fig. S1d). It has been pre-
viously described that DYRK1A phosphorylates NOTCH1 
[41]. In this sense, the specificity of the antibodies and plas-
mids used for DYRK2 detection was analysed (Fig. S1e). In 
addition, DYRK2 effect on endogenous Notch1-IC protein 
levels was reanalysed in DYRK1A knockout cells obtaining 
similar results (Fig. S1f). Then we analysed the effect of 
knocking down DYRK2 using a specific siRNA. In agree-
ment with our previous results, DYRK2 depletion increased 
Notch1-IC levels (Fig. 1c) as well as its half-life (Fig. S1g), 
further proving that Notch1-IC basal levels were regulated 
by DYRK2.
Our results suggested that DYRK2 might negatively 
regulate NOTCH1 protein levels, and thus we hypothesised 
that the endogenous levels of DYRK2 and NOTCH1 might 
show a correlation. To test our hypothesis, we analysed the 
levels of these two proteins in eight different cell lines, and 
as shown in Fig. 1d, a negative correlation was observed. 
Next, to further confirm the ability of this kinase to regu-
late Notch1-IC, DYRK2 knockout cell lines were generated 
by CRISPR/Cas9 gene-editing tools and Notch1-IC protein 
levels were evaluated. As shown in Fig. 1e, specific stable 
DYRK2 knockout resulted in increased levels of Notch1-IC 
in three of the four cell lines tested. In the case of HeLa, 
DYRK2 knockout led to the appearance of faster migrat-
ing bands, which might reflect unphosphorylated NOTCH1. 
Collectively, these results demonstrate that DYRK2 nega-
tively regulates Notch1-IC levels.
Fig. 2  DYRK2 phosphorylates Notch1-IC. a HEK-293T cells were 
transfected to express Myc-Notch1-IC and increasing amounts of 
Flag-DYRK2 wild type (WT) or kinase mutant (KM). Cell lysates 
were analysed by immunoblotting with the indicated antibodies. We 
show a representative blot of four independent experiments. b HEK-
293T cells were transfected to express DYRK2 WT or KM. Twenty-
four hours post-transfection, cells were lysed and protein expres-
sion was analysed by immunoblot with the indicated antibodies. 
We show a representative blot of three independent experiments. c 
HEK-239T cells were co-transfected with the indicated plasmids and 
then treated or not for 12  h with the proteasome inhibitor MG-132 
(10  μM). Cell lysates were analysed by immunoblotting with anti-
Myc and Flag antibodies. We show a representative blot of three 
independent experiments. d HEK-293T cells were transfected with 
the indicated plasmids and treated with MG-132 for 12  h and were 
lysed in phosphatase inhibitor-free buffer in the absence or presence 
of λ-phosphatase. Electrophoretic mobility was determined by immu-
noblotting. We show a representative blot of four independent experi-
ments. e Immunoprecipitated Notch1-IC endogenous protein from 
HEK-293T cells was incubated with DYRK2 recombinant protein in 
the presence or absence of ATP (0.1  μM). Electrophoretic mobility 
was determined by immunoblotting with the indicated antibodies. We 
show a representative blot of four independent experiments. f HEK-
239T cells were co-transfected with the indicated plasmids and after 
36 h treated with MG-132 in the presence or not of harmine for 12 h 
before lysis. Protein expression was analysed by immunoblot with 
the indicated antibodies. We show a representative blot of three inde-
pendent experiments. g Cells were transfected to express HA-Notch1-
IC WT or HA-Notch1-IC T2512A (threonine 2512 mutated to ala-
nine) in the presence or not of Flag-DYRK2 WT. Cells were further 
cultivated and lysed and protein expression was analysed by immuno-
blot with the indicated antibodies. We show a representative blot of 
three independent experiments. h HEK-293T cells were transfected to 
express Myc-Notch1-IC WT or Myc-Notch1-IC T2512A in the pres-
ence or not of Flag-DYRK2-WT or KM and, after 36 h, treated with 
MG-132 for 8 h and lysed. A fraction was subjected to immunopre-
cipitation (IP) using anti-Myc antibody. After elution phosphorylation 
was revealed with an anti-phospho-serine/threonine antibody, while 
exogenous Notch1-IC protein levels were visualised with an anti-Myc 
antibody by western blotting (top panel). The remaining extract frac-
tion was tested for the occurrence of the indicated proteins (lower 
panel). We show a representative blot of three independent experi-
ments
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DYRK2 phosphorylates Notch1‑IC in vivo and in vitro
Based on the capacity of DYRK2 to induce the appearance 
of slower migrating bands compatible with phospho-forms 
of Notch1-IC, next we analysed whether DYRK2 kinase 
activity was necessary for its effect on Notch1-IC levels. 
We co-expressed Notch1-IC with either increasing amounts 
of DYRK2 or a kinase point mutant version (DYRK2 KM). 
As shown in Fig. 2a, DYRK2 overexpression led to a reduc-
tion of Notch1-IC levels concomitant with the appearance 
of upshifted bands. By contrast, Notch1-IC levels were not 
altered in the presence of the DYRK2 KM. Similar results 
were obtained at the endogenous level (Fig. 2b). To test 
whether that reduction in protein levels was mediated by 
protein degradation, we decided to examine this effect in the 
presence or absence of the proteasome inhibitor MG-132. 
As shown in Fig. 2c, the addition of MG-132 consider-
ably prevented DYRK2-mediated Notch1-IC degradation 
and stabilised band mobility. To confirm that the upshifted 
Notch1-IC bands were phosphorylated forms, we incubated 
A B
C D
Fig. 3  DYRK2 regulates Notch1-IC protein levels via Fbxw7-medi-
ated proteasomal degradation. a HEK-293T cells were co-transfected 
to express Notch1-IC together with DYRK2, and the levels were eval-
uated in response to FBXW7 dominant negative (FBXW7-∆Fbox) 
lacking the F-box domain that recruits ubiquitination machinery. 
We show a representative blot of three independent experiments. b 
HEK-293T cells were transfected with Flag-DYRK2 in the presence 
or absence of a dominant-negative form of FBXW7. Endogenous 
Notch1-IC protein levels were evaluated by western blotting. We 
show a representative blot of three independent experiments. c HEK-
293T cells were transfected with expression plasmids encoding Flag-
tagged DYRK2, Myc-tagged Notch1-IC and His-tagged ubiquitin. 
After 36 h, cells were incubated in the presence of MG-132 (10 μM) 
during 12 h and lysed under denaturing conditions. His-tagged ubiq-
uitin was purified with Ni–NTA agarose columns and ubiquitinated 
Notch1-IC was analysed by western blotting. A fraction was tested 
for the occurrence of the indicated proteins (INPUT). We show a rep-
resentative blot of three independent experiments. d Wild-type and 
 DYRK2−/−MDA-MB-231 cells were stimulated or not with MG-132 
during 9  h, lysed and subjected to immunoprecipitation using anti-
Notch1-IC antibody. A small fraction of the lysate was tested for the 
occurrence of Notch1-IC (INPUT). The precipitates were subjected to 
western blot analysis with anti-Notch1-IC or anti-Ubi antibodies. We 
show a representative blot of three independent experiments
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cell extracts with λ-phosphatase in the presence of MG-132. 
As shown in Fig. 2d, λ-phosphatase treatment transformed a 
slower electrophoretic band mobility into a faster migrating 
movement, similar to those obtained in response to DYRK2 
KM expression. To evaluate the ability of DYRK2 to directly 
phosphorylate Notch1-IC, we performed an in vitro kinase 
assay (Fig.  2e). The presence of recombinant DYRK2 
showed the occurrence of upper Notch1-IC bands, which 
appeared only in the presence of ATP. Moreover, the rel-
evance of the DYRK2 kinase activity for Notch1-IC was 
highlighted by experiments with chemical inhibitors. As 
shown in Figure S2a, treatment with the pan-specific DYRK 
inhibitor harmine inhibited the negative effect of DYRK2 
on Notch1-IC levels, and also caused a clear increase in the 
motility of the Notch1-IC bands in the presence of MG-132 
(Fig. 2f). Similar results were obtained with curcumin, 
another DYRK2 inhibitor [42] (Fig. S2b). Altogether, these 
experiments demonstrate that DYRK2 directly phosphoryl-
ates Notch1-IC.
To identify the Notch1-IC sites phosphorylated by 
DYRK2, we analysed different relevant residues mutated 
to alanine involved in Notch1-IC regulation previously 
described [22]. Co-expression of the mutants with DYRK2 
and subsequent analysis of their electrophoretic behaviour 
showed that mutation of Thr-2512 significantly reduced 
DYRK2-mediated Notch1-IC degradation (Fig. S2c). Simi-
lar results were obtained when we compared the co-expres-
sion of DYRK2 with Notch1-IC WT vs T2512A (Fig. 2g), 
indicating that phosphorylation of Thr-2512 is necessary for 
the effect of DYRK2 on Notch1-IC stability. To further prove 
that DYRK2 phosphorylates Notch1-IC in cells, NOTCH1 
WT and T2512A phospho-deficient mutant constructs were 
transfected together with DYRK2 WT or DYRK2 KM, 
immunoprecipitated, and their phosphorylation status was 
analysed with a phospho-serine/threonine antibody (as there 
is no specific phospho-T2512 NOTCH1 antibody available) 
(Fig. 2h). Mutation of Thr-2512 to alanine clearly reduced 
the phosphorylation of Notch1-IC mediated by DYRK2 (by 
comparing lanes 2 and 4). However, DYRK2 was still able 
to induce some phosphorylation in the T2512A Notch1-IC 
mutant, indicating that it might not be the only site phos-
phorylated by DYRK2 in cells. Collectively, these results 
clearly demonstrate that DYRK2-mediated phosphorylation 
of Notch1-IC at threonine 2512 is crucial for its degradation.
DYRK2 regulates proteasomal degradation 
of Notch1‑IC
As shown in Fig. 2c, treatment with the proteasome inhibi-
tor MG-132 restored the level of Notch1-IC upon DYRK2 
expression (lanes 2 and 4). These results indicated that 
DYRK2 decreased the stability of Notch1-IC through a 
ubiquitin/proteasome-dependent process. Based on the 
previous reports showing that Thr-2512 phosphorylation 
facilitated Notch1-IC proteasomal degradation through 
FBXW7 [21], we decided to evaluate if this ubiquitin ligase 
was implicated in the degradation of Notch1-IC mediated 
by DYRK2. To analyse the role of FBXW7 in this process, 
we first co-expressed DYRK2 and Notch1-IC in the pres-
ence or absence of a dominant-negative form of FBXW7 
lacking the F-box (FBXW7ΔFbox). As shown in Fig. 3a, 
FBXW7ΔFbox expression recovered the level of Notch1-IC 
decreased by DYRK2, preserving the reduction of the band 
mobility. Similar results were obtained at the endogenous 
level (Fig. 3b). These results showed that FBXW7 is impor-
tant for the degradation of NOTCH1 mediated by DYRK2.
We next examined the effect of DYRK2 on Notch1-
IC ubiquitination. We co-expressed Myc-Notch1-IC and 
His-Ubiquitin with or without different concentrations 
of DYRK2 and DYRK2 KM in the presence of MG-132 
and analysed the ubiquitination status of Notch1-IC. As 
shown in Fig. 3c, Notch1-IC polyubiquitination became 
more evident in the presence of increasing concentra-
tions of DYRK2. Furthermore, we examined the effect of 
DYRK2 depletion on the basal level of Notch1-IC poly-
ubiquitination, comparing control and  DYRK2−/− cells in 
the presence or absence of MG-132. As shown in Fig. 3d, 
ubiquitination levels of Notch1-IC were significantly lower 
in cells lacking DYRK2. Collectively, these data show that 
DYRK2 promotes basal Notch1-IC polyubiquitination and 
proteasomal degradation via FBXW7.
DYRK2 interacts and colocalizes with Notch1‑IC
Next, we analysed the ability of DYRK2 to interact with 
Notch1-IC. We first co-expressed Myc-Notch1-IC alone or 
in the presence of Flag-DYRK2 and performed coimmuno-
precipitation assays. As shown in Fig. 4a, DYRK2 coim-
munoprecipitated efficiently with Notch1-IC. Then, we 
analysed the subcellular localization of both proteins and 
the effect of DNA damage. Confocal microscopy showed 
that GFP-DYRK2 and endogenous Notch1-IC mainly colo-
calize in the nucleus, with a high degree of nuclear locali-
zation of DYRK2 in cells stimulated with ETP (Pearson’s 
coefficient = 0.65 and Manders’ coefficients of A = 0.789; 
B = 0.773) (Fig. 4b and c).
To map the interaction sites of Notch1-IC with DYRK2, 
first we performed an in vitro interaction peptide array 
experiment. A peptide library consisting of overlapping 
fragments representing the entire Notch1-IC or DYRK2 
proteins was incubated with GST-DYRK2 or GST-Notch1-
IC, respectively, using GST as a control. Detection of 
bound material by antibodies showed six potential bind-
ing regions of Notch1-IC with DYRK2. Likewise, DYRK2 
showed two potential binding regions with Notch1-IC, 
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which correspond to the C-terminal region of the pro-
tein (Fig. S4a and S4b). Next, to validate the functional 
relevance of the regions present in Notch1-IC, all were 
mutated and tested for their interaction with DYRK2 
(Notch1-IC mutant constructs. Fig. S4c). As shown in 
Fig. 4d, the individual mutation of the regions in the RAM 
domain and one adjacent in the ANK (ankyrin) domain 
caused a marked reduction in the ability to coimmunopre-
cipitated efficiently with DYRK2. Furthermore, the ability 
of DYRK2 to negatively regulate Notch1-IC protein levels 
was strongly reduced (Fig. 4e and S4d). All these results 
clearly prove the direct interaction between Notch1-IC 
and DYRK2, and suggest the existence of more than one 
region responsible for binding in both proteins, highlight-
ing the possible relevant role of the RAM domain present 
in Notch1-IC.
Genotoxic stress induces Notch1‑IC degradation 
mediated by DYRK2
Next, we decided to evaluate the physiological relevance of 
the observed effect of DYRK2 on Notch1-IC levels. Among 
the stimuli able to regulate the activity of this kinase, the 
response to DNA damage upon exposure to genotoxic stress 
[30, 35, 36] stands out. Therefore, we tested the ability of 
DNA damage to regulate NOTCH1 signalling via DYRK2. 
HEK-293T cells were stimulated with increasing concen-
trations of DNA-damaging agent adriamycin (ADR) and 
protein levels of both Notch1-IC and DYRK2 were evalu-
ated by western blot. As depicted in Fig. 5a, upregulation of 
DYRK2 in response to ADR was inversely correlated with 
Notch1-IC protein levels. Similar results were obtained in 
MDA-MB-231 cells (Fig. S5a), DYRK1A knockout cells 
(Fig. S5b) and with other genotoxic agents such as etopo-
side and cisplatin in different cell lines (Fig. S5c and S5d). 
Next, we evaluated the consequences of genotoxic stress on 
Notch1-IC transcriptional activity. In agreement with our 
previous results, ADR treatment impaired Notch1-IC tran-
scriptional activity (Fig. 5b). Similar results were obtained 
with HIPK2 knockout cells (Fig. S5e) and after DYRK2 
overexpression (Fig. S5f). We then investigated whether 
modulation of DYRK2 levels affected the transcriptional 
activity of Notch1-IC. As shown in Fig. 5c, ectopic expres-
sion of DYRK2 reduced Notch1-IC transcriptional activity. 
Moreover, Hes5 and Hes1 induction by Notch1-IC at both 
mRNA and protein levels was reduced by DYRK2 over-
expression. Similarly, to demonstrate the role of DYRK2 
kinase activity on the control of Notch1-IC transcriptional 
activity, we used an analogue-sensitive DYRK2 form 
(DYRK2-AS), which presents a mutation in the gatekeeper 
residue and is selectively sensitive to PP1 inhibitors [43]. 
As shown in Figure S5g, the specific inhibition of DYRK2 
activity by PP1 analogue II stimulation reduced drastically 
the effect of DYRK2 on Notch1-IC protein levels with clear 
effects on Hes5 at both mRNA and protein levels. Taken 
together, these results further suggest that DYRK2 modu-
lates Notch1-IC regulation in response to genotoxic stress.
To demonstrate the role of DYRK2 on the regulation of 
Notch1-IC in response to DNA damage, we assessed the 
effect of DYRK2 knockdown with siRNA. As shown in 
Fig. 5d, DYRK2 depletion avoided adriamycin-mediated 
reduction of Notch1-IC (lanes 2 and 5). In the same sense, 
Hes5 and Hes1 expression (RNA and protein) reduced by 
ADR treatment was restored by harmine and DYRK2 knock-
down (lanes 2, 3 and 5) in MDA-MB-231 cells. Similar 
results were obtained in HEK-293T cells (Fig. S5h). Finally, 
we compared the effect of Notch1-IC ectopic expression in 
knockout cells lacking DYRK2. As shown in Figure S5i, 
Notch1-IC-induced expression of luciferase reporter gene 
was higher in DYRK2 knockout cells than in control cells. 
Altogether these data suggest that DYRK2 has a relevant 
role on Notch1-IC protein levels and activity in response to 
DNA damage.
Fig. 4  Notch1-IC interacts and colocalizes with DYRK2. a HEK-
293T cells were transfected with expression plasmids Myc-tagged 
Notch1-IC and Flag-DYRK2 as indicated and after 36 h the protea-
some inhibitor MG-132 was added for another 12 h to avoid Notch1 
degradation. Cells were lysed and subjected to immunoprecipitation 
(IP) using anti-Flag antibody. After elution, Myc-Notch1-IC protein 
was detected by western blotting. A small fraction (5%) of the lysate 
was tested for the occurrence of the indicated proteins by immuno-
blot (INPUT). The positions and molecular weights (in kDa) are 
indicated. We show a representative blot of three independent experi-
ments. b CHO cells were transfected with GFP-DYRK2 and analysed 
for the subcellular localization of DYRK2 and endogenous Notch1-
IC proteins by confocal microscopy stimulated or not during 6  h 
with ETP (10 μM). Nuclear DNA was stained with DAPI. We show 
a representative picture where overlapping localization in merged 
pictures is shown in yellow. c Fluorescence intensity profiles through 
the white line shown indicate GFP-DYRK2 and Notch1-IC cellular 
localization in both control and DNA damage conditions. Pearson’s 
coefficient (0.65) and thresholded Manders’ coefficients A and B 
(A = 0.789; B = 0.773) were calculated for both situations. d HEK-
293T cells were transfected with Flag-DYRK2 and HA-Notch1-IC 
plasmids (WT and mutant versions) as indicated, and after 36 h the 
proteasome inhibitor MG-132 (10 μM) was added for another 12 h. 
Cells were lysed, subjected to immunoprecipitation (IP) using anti-
Flag antibody and the different proteins detected by western blotting 
(left panel). A small fraction (5%) of the lysate was tested by immu-
noblot for the occurrence of the indicated proteins (INPUT, right 
panel). We show a representative blot of three independent experi-
ments. e HEK-293T cells were co-transfected with HA-Notch1-IC 
or the indicated mutants either alone or along with DYRK2. After 
36 h, cells were lysed and the stability of Notch1-IC was revealed by 
immunoblotting. We show a representative blot of three independent 
experiments
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DYRK2 modulation modifies Notch1‑IC physiological 
effects
Finally, in order to investigate the clinical significance of our 
findings, we first analysed data from the public database The 
Human Protein Atlas to determine the protein abundance of 
DYRK2 and NOTCH1 in tumour tissues. As we previously 
observed in different cell lines, a considerable number of 
tissues present in a high number of patients showed low 
levels of DYRK2 expression and a high NOTCH1 abun-
dance, from which the differences observed in ovarian, cer-
vical, colorectal or pancreatic cancer stand out (Fig. 6a). 
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Similarly, the analysis of the frequency of loss-of-function 
mutations on DYRK2 and/or NOTCH1 in tumours showed 
that mutations on DYRK2 and NOTCH1 occur very rarely 
together, suggesting that both proteins might be in the same 
pathway (Fig. 6b). Next, we examined the effect of DYRK2 
modulation on cell viability and apoptosis in response to 
ADR. We observed that knocking down DYRK2 in MDA-
MB-231 cells increased cell viability in response to ADR 
(Fig. 6c). However, the opposite effect was observed with 
cells overexpressing DYRK2, showing a strong reduction 
on cell survival in response to ADR. In the same context, 
the percentage of apoptotic cells upon exposure to ADR 
was increased by DYRK2 overexpression, and a signifi-
cant reduction was observed in the presence of harmine in 
MDA-MB-231 (Fig. 6d) and MDA-MB-468 cells (Fig. S6a). 
Similarly, DYRK2 overexpression affected the expression 
of genes involved in cell viability such as BCL2 (Fig. S6b). 
Additionally, DYRK2 is necessary for adriamycin-induced 
suppression of cell invasion (Fig. 6e). Finally, cell motility 
experiments in MDA-MB-231 (Fig. 6f) and MDA-MB-468 
cells (Fig. S6c) showed that, although in the presence of 
DYRK2 the protein levels of Notch1-IC affected cancer cell 
migration significantly, Notch1-IC overexpression consid-
erably increased cell migration of DYRK2-KO cells, sug-
gesting that DYRK2 restrains Notch1-mediated cancer cell 
migration. Associated with these results, changes in the 
expression of genes related with mobility and invasion, such 
as FGF, TFG-β, TNF or OCT-4, were observed (Fig. S6d). 
Altogether, these results indicate a new role of DYRK2 in 
cancer cell migration/invasion through the regulation of 
Notch1-IC levels.
Discussion
In the present work, we describe DYRK2 as a new kinase 
that regulates NOTCH1 pathway via phosphorylation, con-
trolling its protein levels and activity in response to DNA 
damage. Different reports have shown how some kinases 
have the ability to regulate Notch1-IC by phosphorylation, 
thus facilitating its subsequent ubiquitination. Phosphoryla-
tion of the PEST domain is a substrate for recognition by 
FBXW7, which binds directly to Notch1-IC promoting its 
polyubiquitination and proteasomal degradation recruiting 
the components of an SCF ubiquitin ligase complex degra-
dation [18, 20, 21]. Although different kinases such as cyclin 
C and various CDKs (CDK3, CDK8 and CDK19) [44] have 
been described able to regulate Notch1-IC by phosphoryla-
tion of the PEST domain, requirement of previous Thr-2512 
phosphorylation for FBXW7 interaction has been described 
in bibliography [22, 23]. To date, to our knowledge, only 
MEKK1 and HIPK2 have been described to be able to phos-
phorylate Thr-2512 and promote proteasomal degradation of 
Notch1-IC by this pathway [18, 25]. Our findings show that 
DYRK2 is also able to directly phosphorylate Notch1-IC at 
Thr-2512 in the PEST domain and facilitate its proteasomal 
degradation.
Our results related to the interaction between Notch1-IC 
and DYRK2 suggest the possible relevant role of the RAM 
domain present in Notch1-IC. Previous studies suggested 
that the primary function of the RAM region is to recruit 
Notch1-IC to CSL [45, 46], which, together with MAML1, 
stimulate the transcription of target genes. In this sense, fur-
ther studies should be done to clarify whether the interaction 
with DYRK2 in response to some stimuli could presumably 
inhibit Notch1-IC downstream signalling through interaction 
with this domain.
It is also important to mention the evolutive proximity 
between DYRK2 and HIPK2. Both kinases belong to the 
CMGC group and are evolutionarily very close [26]. They 
are both ubiquitinated by MDM2 [36, 47] and SIAH2 ubiq-
uitin ligases, and present both common and specific sub-
strates for each of them [30, 48]. Similarly, although both 
respond to certain common stimuli, they may also be present 
in some pathways exclusively. In the specific case of cel-
lular response to DNA damage stimulus, both kinases are 
able to phosphorylate p53 at Ser46 to irreversibly induce 
p53-dependent apoptosis [35, 49]. Our findings indicate that 
Notch1-IC regulation seems to be also common for both 
Fig. 5  Genotoxic stress affects Notch1-IC signalling via DYRK2. 
a HEK-293T cells were stimulated with increasing concentra-
tions of ADR for 12  h, lysed and endogenous levels of Notch1-IC 
and DYRK2 measured by immunoblotting. We show a representa-
tive blot of four independent experiments. b HEK-293T cells were 
transfected with the indicated plasmids and the 4xCSL-luciferase 
reporter and 24 h later stimulated with the indicated doses of ADR 
for another 12 h. Cells were lysed and one aliquot was used for the 
luciferase reporter assay (upper panel), while another fraction was 
used to analyse the levels of the indicated protein by immunoblot. We 
show a representative blot of three independent experiments. Data are 
mean ± SD of n = 3 experiments. *P < 0.05, **P < 0.01, ***P < 0.001. 
c HEK-293T cells were transfected with the indicated plasmids. One 
aliquot was used for the luciferase reporter assay and immunob-
lot (upper panel), while another was used to analyse Hes5 and Hes1 
mRNA levels by qPCR (lower panel). We show a representative 
blot of three independent experiments. Data are mean ± SD of n = 3 
experiments. ***P < 0.001. d MDA-MB-231 cells were transfected 
with DYRK2 or scrambled (control) siRNAs and, after 3 days of cul-
ture, stimulated or not with ADR (2 μg/ml) for 12 h in the presence 
or absence of harmine (5 μM). One fraction was used to analyse the 
levels of the indicated protein by immunoblot (upper panel), while 
another was used to analyse Hes5 and Hes1 mRNA levels by qPCR 
(lower panel). We show a representative blot of three independent 
experiments. Data are mean ± SD of n = 3 experiments. *P < 0.05, 
***P < 0.001
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kinases, being the action mechanism of DYRK2 described 
in this study HIPK2 independent (Figure S5e and data not 
shown). The concerted regulation in response to DNA dam-
age of Notch1-IC executed by DYRK2 and also HIPK2 may 
represent a fail-safe mechanism to ensure a corrected reduc-
tion of Notch1-IC levels in this context. However, further 
studies should be done to elucidate the connection between 
these two pathways. Similarly, analysing the response of 
Notch1-IC to other stimuli able to regulate the activity or 
expression of DYRK2, such as hypoxia [30], serum starva-
tion [50], β-adrenergic stimulation [51], LPS [52] or heat 
shock [37], would be of interest.
In the context of chemotherapy resistance, one of the 
most important problems in cancer treatment, understanding 
the molecular mechanisms implicated in the DNA damage 
response (DDR) pathway is crucial. In this sense, it has been 
reported that overexpression of Notch1-IC in lung and liver 
cancer cells increases resistance to cisplatin [53, 54]. Simi-
larly, NOTCH1 plays a direct negative regulatory role on 
DDR following ionising radiation treatment by interacting 
with ATM and disrupting its activation [55]. On the other 
hand, Li et al. [56], recently described that cisplatin induces 
expression of Notch1-IC in a dose-dependent manner in cer-
vical cancer cells. In fact, in some specific types of tumours 
such as skin cancer, small cell lung cancer or hepatocellular 
carcinoma, contradictory data indicate that NOTCH1 signal-
ling could be playing anti-proliferative rather than oncogenic 
roles [57]. In this study, we provide new insights into the 
consequences of exposure to DNA damage on the NOTCH1 
signalling pathway, since different chemotherapeutic agents 
(adriamycin, etoposide or cisplatin) promote Notch1-IC inhi-
bition mediated by DYRK2 in different cell lines.
Previous studies have broadly shown that perturbation 
of the NOTCH1 signalling pathway is linked to the patho-
genesis of important lung diseases, in particular, lung can-
cer and lung lesions [58, 59]. However, it has also been 
proved to play a key role in breast cancer [60, 61] and 
prostate cancer [62]. Additionally, Notch1-IC aberrant 
overexpression correlates with leukaemia [63] and breast 
cancer [9, 64]. Although DYRK2 distinct role in cancer 
development has been broadly proved, there is controversy 
concerning its pro- or anti-tumour potentials. However, 
various studies have shown that DYRK2 is down-regulated 
in various cancer tissues such as lung, breast, prostate and 
colon, associated with poor patient prognosis [32, 50, 
65–69]. The data showing the correlation in the levels of 
both proteins in tumour tissue (Fig. 6a) agree with our 
in vitro data and suggest that the degradation of Notch1-IC 
by DYRK2 might also be relevant in cancer patients. Addi-
tionally, our results prove that DYRK2 Thr-2512 direct 
phosphorylation is an important milestone in Notch1-IC 
regulation. These results might clarify previous analyses 
focused on the relevance of Thr-2515 mutation in some 
cancers such as human T cell acute lymphoblastic leu-
kaemia [70].
In summary, our results show the ability of DYRK2 to 
regulate Notch1-IC stability affecting its transcriptional 
activity. In response to DNA damage, DYRK2 phosphoryl-
ated Notch1-IC and facilitated its proteasomal degradation 
by FBXW7 (Fig. 7). We propose that this new regulatory 
mechanism induced by chemotherapeutic agents has an 
influence on cancer cells behaviour. Further studies are 
needed to understand the potential implications for those 
tumours with over-expressed Notch1-IC.
Fig. 6  DYRK2 inhibition increases Notch1-IC tumorigenesis effect in 
breast cancer. a DYRK2 and NOTCH1 protein abundance in tumour 
tissues obtained from The Human Protein Atlas. Column and circle 
colour show the antibody stain level observed in tumour tissues. The 
point size indicates the number of patients showing particular expres-
sion to the total patients. The tumour tissues were sorted based on 
the abundance score differences between proteins. To calculate this, 
every staining level was assigned to a number (Not detected: 1, Low: 
2, Medium: 3 and High: 4) and multiplied by the number of patients 
for each tissue and protein. Then, the absolute mean differences were 
calculated for every tumour tissue. b DYRK2 and NOTCH1 mutation 
frequency separately or together (missense, non-sense or deep dele-
tions) for every tumour type included in the TCGA PanCancer data-
set. c MDA-MB-231 cells were transfected with DYRK2 or scram-
bled (control) siRNAs or Flag-DYRK2 as indicated, and after 48  h 
of culture stimulated or not with ADR (2 μg/ml). Cell viability was 
determined using YOYO-1 fluorescence. Data are mean ± SD of n = 3 
experiments. **P < 0.01, ***P < 0.001. d MDA-MB-231 cells were 
transfected or not with Flag-DYRK2 and after 36 h of culture stimu-
lated or not with ADR (2 μg/ml) for 12 h in the presence or absence 
of harmine (5  μM) and used for apoptosis analysis by Annexin V/
PI staining. Cell viability was measured by flow cytometry. Data are 
mean ± SD of n = 3 experiments. **P < 0.01, ***P < 0.001. e MDA-
MB-231 WT and DYRK2 −/− cells were stimulated or not with ADR 
(2  μg/ml) for 12  h and used for matrigel motility assays. Data are 
mean ± SD of n = 3 experiments. ***P < 0.001. f MDA-MB-231 WT 
and DYRK2 −/− cells were transfected or not with Flag-Notch1-IC 
and after 36  h used for cell motility assays. Data are mean ± SD of 
n = 3 experiments. *P < 0.05, ***P < 0.001
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